Literature DB >> 32042274

Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?

Yaowen Zhang1,2, Carlos Ascaso1, Antonio Herreros1,2, Joan Sánchez3, Sebastia Sabater4, Marta Del Pino5, Yan Li1,2, Gabriela Gómez2,6, Aureli Torné5, Albert Biete1,2,5, Ángeles Rovirosa1,2,5.   

Abstract

AIM: To analyse the possible relationship between the EQD2(α/β=3Gy) at 2 cm3 of the vagina and late toxicity in vaginal-cuff-brachytherapy (VBT) after external-beam-irradiation (EBRT) for postoperative endometrial carcinoma (EC).
MATERIALS AND METHODS: From 2014 to 2016, 62 postoperative EC patients were treated with EBRT + VBT. The median EBRT dose was 45 Gy (44 Gy-50.4 Gy). VBT involved a single 7 Gy dose. Toxicity was prospectively evaluated using the RTOG score for the rectum and bladder and the objective LENT-SOMA criteria for the vagina. EQD2(α/β = 3Gy) at 2 cm3 of the most exposed part of the vagina was calculated by the sum of the EBRT + VBT dose. Statistics: Boxplot, Student's t and Chi-square tests and ROC curves.
RESULTS: Mean follow-up: 39.2 months (15-68). Late toxicity: bladder:0 patient; rectum:2 patients-G1; Vagina: 26 patients-17G1, 9G2; median EQD2(α/β=3Gy) at 2 cm3 in G0-G1 patients was 70.4 Gy(SD2.36), being 72.5 Gy(SD2.94) for G2p. The boxplot suggested a cut-point identifying the absence of G2: 100 % of G2p received >68 Gy, ROC curves showed an area under the curve of 0.72 (sensitivity of 1 and specificity of 0.15).
CONCLUSIONS: Doses >68 Gy EQD2(α/β=3Gy) at 2 cm3 to the most exposed area of the vagina were associated with late G2 vaginal toxicity in postoperative EC patients treated with EBRT + VBT suggesting a very good dose limit to eliminate the risk of G2 late toxicity. The specificity obtained indicates the need for prospective analyses.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Late vaginal toxicity; Postoperative endometrial cancer

Year:  2020        PMID: 32042274      PMCID: PMC7000548          DOI: 10.1016/j.rpor.2020.01.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  27 in total

Review 1.  Consensus on treatment of endometrium carcinoma with brachytherapy.

Authors:  J L Guinot; J Pérez-Calatayud; J M Azcoaga; I Herruzo; C Bodineau; A Rovirosa; V Crispín; P Galán; E González-Patiño; J Pérez-Regadera; A Polo
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer.

Authors:  Agnes Y Bahng; Avner Dagan; Deborah W Bruner; Lilie L Lin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-06       Impact factor: 7.038

3.  Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery.

Authors:  I L Atahan; E Ozyar; F Yildiz; G Ozyigit; M Genc; S Ulger; A Usubutun; F Köse; K Yuce; A Ayhan
Journal:  Int J Gynecol Cancer       Date:  2008-02-15       Impact factor: 3.437

4.  Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer.

Authors:  Irene Chong; Peter J Hoskin
Journal:  Brachytherapy       Date:  2008-03-20       Impact factor: 2.362

5.  Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study.

Authors:  Bengt Sorbe; Britta Nordström; Johanna Mäenpää; Janez Kuhelj; Dimitrij Kuhelj; Sait Okkan; Jean-Francois Delaloye; B Frankendal
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

6.  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.

Authors:  William Small; Loren K Mell; Penny Anderson; Carien Creutzberg; Jennifer De Los Santos; David Gaffney; Anuja Jhingran; Lorraine Portelance; Tracey Schefter; Revathy Iyer; Mahesh Varia; Kathryn Winter; Arno J Mundt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-26       Impact factor: 7.038

7.  External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study--quality-of-life analysis.

Authors:  Bengt Göran Sorbe; György Horvath; Håkan Andersson; Karin Boman; Caroline Lundgren; Birgitta Pettersson
Journal:  Int J Gynecol Cancer       Date:  2012-09       Impact factor: 3.437

8.  Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit?

Authors:  Concetta Laliscia; Durim Delishaj; Maria Grazia Fabrini; Alessandra Gonnelli; Riccardo Morganti; Franco Perrone; Roberta Tana; Fabiola Paiar; Angiolo Gadducci
Journal:  J Contemp Brachytherapy       Date:  2016-12-09

9.  Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities.

Authors:  Günter Emons; Eric Steiner; Dirk Vordermark; Christoph Uleer; Nina Bock; Kerstin Paradies; Olaf Ortmann; Stefan Aretz; Peter Mallmann; Christian Kurzeder; Volker Hagen; Birgitt van Oorschot; Stefan Höcht; Petra Feyer; Gerlinde Egerer; Michael Friedrich; Wolfgang Cremer; Franz-Josef Prott; Lars-Christian Horn; Heinrich Prömpeler; Jan Langrehr; Steffen Leinung; Matthias W Beckmann; Rainer Kimmig; Anne Letsch; Michael Reinhardt; Bernd Alt-Epping; Ludwig Kiesel; Jan Menke; Marion Gebhardt; Verena Steinke-Lange; Nils Rahner; Werner Lichtenegger; Alain Zeimet; Volker Hanf; Joachim Weis; Michael Mueller; Ulla Henscher; Rita K Schmutzler; Alfons Meindl; Felix Hilpert; Joan Elisabeth Panke; Vratislav Strnad; Christiane Niehues; Timm Dauelsberg; Peter Niehoff; Doris Mayr; Dieter Grab; Michael Kreißl; Ralf Witteler; Annemarie Schorsch; Alexander Mustea; Edgar Petru; Jutta Hübner; Anne Derke Rose; Edward Wight; Reina Tholen; Gerd J Bauerschmitz; Markus Fleisch; Ingolf Juhasz-Boess; Sigurd Lax; Ingo Runnebaum; Clemens Tempfer; Monika J Nothacker; Susanne Blödt; Markus Follmann; Thomas Langer; Heike Raatz; Simone Wesselmann; Saskia Erdogan
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-11-26       Impact factor: 2.915

10.  Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction(α/β=3Gy) at 2 cm3 of vagina.

Authors:  María Del Valle Aguilera; Ángeles Rovirosa; Carlos Ascaso; Antonio Herreros; Joan Sánchez; Julia Garcia-Migue; Stephanía Cortes; Eduardo Agusti; Cristina Camacho; Yaowen Zhang; Yan Li; Sebastià Sabater; Aureli Torne; Meritxell Arenas
Journal:  J Contemp Brachytherapy       Date:  2018-02-28
View more
  4 in total

1.  Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.

Authors:  Y Zhang; G Gomez; C Ascaso; A Herreros; B Fornes; J Mases; J Rochera; L Tagliaferri; S Sabater; A Torne; A Biete; Á Rovirosa
Journal:  Clin Transl Oncol       Date:  2021-12-01       Impact factor: 3.340

2.  In Vivo Verification of Treatment Source Dwell Times in Brachytherapy of Postoperative Endometrial Carcinoma: A Feasibility Study.

Authors:  Antonio Herreros; José Pérez-Calatayud; Facundo Ballester; Jose Barrera-Gómez; Rosa Abellana; Joana Melo; Luis Moutinho; Luca Tagliaferri; Ángeles Rovirosa
Journal:  J Pers Med       Date:  2022-05-31

3.  Translation and Expression of Professional Terms of Public Emergencies in External Reports.

Authors:  Zhanwei Zhu; Chenhui Wang
Journal:  J Environ Public Health       Date:  2022-09-30

4.  Vaginal cuff brachytherapy: do we need to treat to more than a two-centimeter active length?

Authors:  Garrett L Jensen; Parul N Barry; Harriet Eldredge-Hindy; Scott R Silva; Sarah L Todd; Kendall P Hammonds; Walker R Zimmerman; Daniel S Metzinger; Moataz N El-Ghamry
Journal:  J Contemp Brachytherapy       Date:  2021-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.